Attached files
| file | filename |
|---|---|
| EX-10.1 - EX-10.1 - EMMAUS LIFE SCIENCES, INC. | emma-ex101_7.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): March 29, 2018
Emmaus Life Sciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware |
000-53072 |
41-2254389 |
|
(State or Other Jurisdiction of Incorporation |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 |
||
|
(Address, including zip code, off principal executive offices) |
||
|
|
||
|
Registrant’s telephone number, including area code 310-214-0065 |
||
|
|
||
|
(Former Name or Former Address, if Changed Since Last Report) |
||
|
|
||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d2(b)) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter) Emerging growth company☐
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13a) of the Exchange Act. |
☐ |
On March 29, 2018, Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) entered into a Securities Repurchase Agreement with Sarissa Capital Offshore Master Fund LP, or Sarissa, under which we have repurchased from Sarissa 700,000 shares of our common stock and common stock purchase warrants to purchase up to 800,000 shares of our common stock for a cash price of $7.5 million.
The Securities Repurchase Agreement contains customary representations and warranties of the parties.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
|
Description |
|
10.1 |
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date |
April 4, 2018 |
|
|
EMMAUS LIFE SCIENCES, INC. |
|
|
|
|
|
|
|
|
|
|
By |
/s/ Willis C. Lee |
|
|
|
|
|
Willis C. Lee |
|
|
|
|
|
Chief Operating Officer & Chief Financial Officer |
3